QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations.

The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention globally. The global QuantiFERON World TB Day event will take place online on March 24, 2026, with two identical sessions to enable participation across regions. To learn more and reserve a free spot, visit https://worldtbday.qiagen.com/.

A study recently published in BMC Public Health evaluated TB infection screening strategies among adults living with HIV in Thailand and found that QFT-Plus testing reduced the modeled lifetime risk of progression to active TB by 41% compared with the tuberculin skin test (TST), while also lowering overall lifetime healthcare costs. More accurate detection of TB infection can help clinicians initiate preventive therapy earlier and support more efficient use of healthcare resources.